MedTrace Logo

Effect and Safety Study of Atorvastatin to Treat Chronic Subdural Hematoma

NCT02024373 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2016-10-25

No results posted yet for this study

Summary

To evaluate the clinic effects and security of oral administration of Atorvastatin on chronic subdural hematoma (CSDH).

Conditions

  • Chronic Subdural Hematoma

Interventions

DRUG

Atorvastatin

20 mg (every evening orally) for 8 weeks

DRUG

placebo

20 mg (every evening orally) for 8 weeks

Sponsors & Collaborators

  • Oriental Neurosurgery Evidence-Based-Study Team

    lead OTHER

Principal Investigators

  • Ning jian zhang, MD, PhD · Tianjin Medical University General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2016-04-30
Completion
2016-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02024373 on ClinicalTrials.gov